Setterwalls advises Alligator Bioscience in connection with a capital raise of approximately SEK 120 million and renegotiation of loan

Setterwalls advises Alligator Bioscience AB (“Alligator”), listed on Nasdaq Stockholm, in connection with a rights issue of units of approximately SEK 120 million and renegotiation of the company’s outstanding loan with Fenja Capital II A/S.

The transaction strengthens the company’s financial position and supports the continued clinical development of Alligator’s tumor-targeted immuno-oncology antibody drug candidates.

Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company’s shares are listed on Nasdaq Stockholm and is headquartered in Medicon Village in Lund, Sweden.